secwatch / observer
8-K filed March 17, 2023, 7:59 PM ET ticker ASPI CIK 0001921865
other material confidence high sentiment neutral materiality 0.50

ASP Isotopes raises ~$5M in private placement of common stock and warrants

ASP Isotopes Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ASP Isotopes Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering (effective 2023-02-15).

Action
entry
Agreement
underwriting
Counterparty
H.C. Wainwright & Co., LLC
Value
a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering
Effective
2023-02-15
Exact text from the filing
The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as the Company’s exclusive placement agent in connection with the Offering, pursuant to the engagement letter (the “Engagement Letter”), dated as of February 15, 2023, between the Company and the Placement Agent.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ASP Isotopes Inc. entered into Securities Purchase Agreement with a single institutional investor valued at approximately $5 million (effective 2023-03-14).

Action
entry
Agreement
equity purchase
Counterparty
a single institutional investor
Value
approximately $5 million
Effective
2023-03-14
Exact text from the filing
On March 14, 2023, ASP Isotopes Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”)
View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

ASP Isotopes Inc. filing history →

Source: SEC EDGAR
accession 0001477932-23-001555
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.